March 18, 2024 |
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.
I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:
Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:
Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Pam Cusick, Senior Vice President of Rare Patient Voice, dives into diversity, equity, and inclusion in Pharma and clinical trials; ways to enhance the patient’s voice in their treatment journey…
Jón Ingi Bergsteinsson, Co-founder & CCO at SMART-TRIAL, explores the barriers to, and benefits of, digitalization of clinical operations and trials in the MedTech industry, plus much more!
With our growing dependence on social media, Digital Opinion Leaders are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and…
Omri Shor, Co-founder & CEO of Medisafe, explores how Pharma companies can use digital therapeutics for advancing and supporting the patient journey, how new digital health tools are driving deeper…
Earlene Biggs, VP of Market Research & Analytics at ICON, explores best practices for life science market research and actionable analytics. She also shares her tips for creating organizational wellbeing…
Aubrey de Grey, Chief Science Officer at SENS Research Foundation, discusses a range of interesting topics surrounding innovative interventions and technologies that could not just postpone, but theoretically reverse, age-related…
At Impetus Digital, we pride ourselves with being the spark behind sustained healthcare stakeholder communication, collaboration, education, and insight-synthesis. Our most popular service is online advisory boards. However, there is a myriad of…
Harry Glorikian, Author & General Partner at Scientia Ventures, dives into the current and future applications of AI and other innovative health technologies, including for personalized medicine, drug development, public…
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how innovative medical devices and software can improve…
Although many people are starting to go back to their offices, at least for part of the week, many others are looking at permanent ‘Work From Home’ (WFH) set-ups. At…
